Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News CRT 2021

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

Yael L. Maxwell

March 18, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Opinion CV Team Dispatch

March 2020 News Roundup

L.A. McKeown

March 12, 2020

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Conference News CRT 2018

Time to Shine: ‘Historic’ All-Female Team Takes Over Live Case at CRT 2018

Michael O'Riordan

March 06, 2018

News Industry News

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

October 14, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

Advertisement

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 2020 News Roundup

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Time to Shine: ‘Historic’ All-Female Team Takes Over Live Case at CRT 2018

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content